British Pharmacopoeia Commission appoints five new members

They will take the role for a four-year period

The British Pharmacopoeia (BP) Commission has appointed five new members for a period of four years.

They include: Andrew Coulson, who has been a member of The Royal College of Veterinary Surgeons since 1976. He is a trustee, director and company secretary to the Ripon Council for Voluntary Services, responsible for the financial conduct of a £1m organisation and completion of legal responsibilities as a registered charity and as a limited company.

Gerard Lee was employed by the Medicines and Healthcare products Regulatory Agency (MHRA) between 1999 and December 2011, most recently as group manager of the British Pharmacopoeia and Laboratory Services section (since 2004) and as secretary and scientific director of the BP Commission (since 2002).

Ronald Torano has worked in various capacities at GlaxoSmithKline (GSK) since 1989, culminating in his current post of pharmacopoeial intelligence and advisory specialist.

Paul Varley has been at Medimmune since 1998 and is now vice president of biopharmaceutical development.

Professor John Miller has been visiting professor to the Strathclyde Institute of Pharmacy and Biomedical Sciences at the University of Strathclyde since 2003. Between 1983 and his retirement in 2009 he was employed by the Council of Europe, culminating in the role of head of the laboratory department at the EDQM.

You may also like

Regulatory

MHRA approves beremagene geperpavec gene therapy gel for DEB from birth

The MHRA has approved beremagene geperpavec (Vyjuvek), a topical gene therapy gel for wounds in patients with dystrophic epidermolysis bullosa (DEB), for use from birth onwards
Pharmaceutical

MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients

The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
Regulatory

MHRA opens Northern Ireland hub in Belfast to bring regulatory expertise closer to local life sciences sector

The new hub, hosted by Invest Northern Ireland in Belfast, will offer local healthcare and life sciences stakeholders direct in-person access to MHRA technical experts on topics including innovation pathways, clinical investigations and regulatory support throughout the product development pipeline
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

MC EXCLUSIVE: MHRA on a mission to redefine UK gene therapy

The UK's medicines regulator is seeking industry input on a landmark overhaul of gene therapy medicinal product definitions — the first substantive update in more than two decades — as synthetic mRNA and CRISPR-based technologies outpace the legal framework designed to govern them
Regulatory

MHRA launches consultation to modernise UK gene therapy medicinal product definitions

The UK regulator is seeking industry feedback on proposed updates to the legal classification of GTMPs, as advances in synthetic biology and gene editing outpace definitions set more than a decade ago
Packaging

Amarox recalls sertraline batch after citalopram blister strips found inside sealed cartons

The MHRA has issued a class two recall of one batch of Amarox's sertraline 100 mg film-coated tablets following a secondary packaging error that resulted in citalopram 40 mg blister strips being included in sealed cartons
Regulatory

MHRA report shows agency met targets and closed year in financial surplus

The UK government agency has reported meeting or exceeding every statutory performance target in the 2025/26 financial year, closing in financial surplus while advancing clinical trials reform and AI regulation
Subscribe now